Business Context and Reporting Period
Company: Oric Pharmaceuticals, Inc. (ORIC)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: Oric is a clinical-stage biopharmaceutical company focused on overcoming resistance in cancer. Its primary product candidates include ORIC-114 (EGFR/HER2 exon 20 inhibitor), ORIC-944 (PRC2 allosteric inhibitor), and ORIC-533 (CD73 inhibitor). The company has no approved products and has not generated any revenue.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(56,974) | $(46,889) |
| Net Loss Per Share (Basic & Diluted) | $(0.83) | $(1.03) |
| Research & Development Expenses | $50,900 | $38,303 |
| General & Administrative Expenses | $14,107 | $12,367 |
| Cash, Cash Equivalents & Investments | $308,532 | $235,039 |
| Accumulated Deficit | $(491,901) | $(381,119) |
| Net Cash Used in Operating Activities | $(55,811) | $(41,773) |
| Net Cash Provided by Financing Activities | $125,846 | $85,174 |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the six months ended June 30, 2024, increased by approximately $10.1 million compared to the same period in 2023, driven primarily by higher R&D expenses.
- R&D Expense Growth: R&D expenses rose by $12.6 million (33% increase) year-over-year. This was driven by a $9.3 million increase in external costs related to the advancement of ORIC-114 and ORIC-944, and a $3.3 million increase in internal personnel costs.
- Liquidity Improvement: Total cash, cash equivalents, and investments increased by approximately $73.5 million to $308.5 million. This increase was primarily due to a private placement of common stock in January 2024, which generated gross proceeds of $125.0 million.
- Stock-Based Compensation: Total stock-based compensation expense increased to $9.954 million for the six months ended June 30, 2024, from $7.439 million in the prior year period.
Guidance, Outlook, and Risks
- Capital Runway: Management believes existing cash, cash equivalents, and investments are sufficient to fund operations into late 2026.
- Future Funding: The company expects to incur significant losses for the foreseeable future as it advances clinical trials. It may seek additional financing through equity, debt, or strategic collaborations, which could result in dilution.
- Clinical Progress:
- ORIC-114: Phase 1b dose expansion cohorts initiated for NSCLC patients; updated data expected in the first half of 2025.
- ORIC-944: Dosing initiated in combination with darolutamide and apalutamide in metastatic prostate cancer trials. Collaborations with Bayer and Johnson & Johnson were announced in mid-2024.
- ORIC-533: Completing Phase 1b trial in multiple myeloma; evaluating strategic partnerships for combination therapies.
- Key Risks:
- Regulatory Approval: No assurance that product candidates will receive FDA or other regulatory approvals.
- Financial: Dependence on capital markets; inability to raise additional funds could force reduction of operations.
- Third-Party Dependence: Reliance on third-party manufacturers for drug supply and CROs for clinical trials.
- Legal/Compliance: The company's Chief Business Officer was found liable for insider trading in an unrelated matter in April 2024, which may impact his ability to serve as an officer.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $55.8 million operating cash burn over the six-month period against the projected runway into late 2026.
- Capital Raise Terms: Review the details of the January 2024 private placement ($125M gross proceeds) and the status of the $200M ATM facility.
- Clinical Milestones: Monitor upcoming data readouts for ORIC-114 (expected H1 2025) and the progress of combination trials for ORIC-944.
- Management Stability: Assess the potential impact of the Chief Business Officer's legal issues on company operations and governance.
- Collaboration Agreements: Review the terms and potential revenue implications of the new collaborations with Bayer and Johnson & Johnson.